USPTO Art Unit 1637 Prosecution Statistics

Art Unit Information

Art Unit: 1637
Group: 1630
Tech Center: 1600
Total Cases: 14,297
Last Active: December 2024

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19007278COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSIONDecember 2024April 2025Allow400YesNo
18955967DRUGS FOR PREVENTION OR TREATMENT OF SEPSISNovember 2024January 2025Allow200NoNo
18864911SIRNA SPECIFICALLY BINDING TO M2 MACROPHAGE CD206 AND APPLICATION THEREOFNovember 2024June 2025Allow710NoNo
18942162METHOD OF SEQUENCING A NUCLEIC ACID OF INTERESTNovember 2024June 2025Allow720YesNo
18930307METHOD FOR PREVENTING DSRNA BACTERIAL SOLUTIONS FROM BEING DEGRADED BY UVLIGHT AND APPLICATION THEREOF IN CONTROL OF SILVERLEAF WHITEFLIESOctober 2024March 2025Allow410NoNo
18899181Compositions and Methods of Generating Novel amiRNASeptember 2024April 2025Allow701NoNo
18800329BEAUVERIA BASSIANA STRAIN WITH HIGH ULTRAVIOLET RADIATION RESISTANCE AS WELL AS DIRECTIONAL MUTAGENESIS METHOD THEREFOR AND USE THEREOFAugust 2024May 2025Allow1011YesNo
18801051SYNTHETIC SELF-AMPLIFYING MRNA MOLECULES WITH SECRETION ANTIGEN AND IMMUNOMODULATORAugust 2024May 2025Allow911YesNo
18793716APPLICATION OF MECHANICAL-FORCE SENSITIVE MACROPHAGE SUBSET IN PANCREATIC CANCER DIAGNOSIS OR PROGNOSIS EVALUATIONAugust 2024June 2025Allow1020NoNo
18782965METHOD FOR TREATING C. ACNES BACTERIA-ASSOCIATED DISEASESJuly 2024May 2025Allow1011YesNo
18781699RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USEJuly 2024June 2025Allow1111NoNo
18755160mRNA Capping Enzyme And Methods of Use ThereofJune 2024July 2025Abandon1201NoNo
18752290MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNASJune 2024January 2025Allow701NoNo
18751048ADVANCED RNA TARGETING (ARNATAR) FOR ANGIOTENSINOGENJune 2024December 2024Allow611YesNo
18660600COMPOUNDS TARGETING PMP22 FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH DISEASEMay 2024April 2025Allow1111YesNo
18654906REAGENTS AND METHODS USED IN DEPROTECTION OF 3'-O-AMINO POLYNUCLEOTIDESMay 2024October 2024Allow511YesNo
18640905INHIBITORS OF EXPRESSION AND/OR FUNCTIONApril 2024March 2025Allow1110NoNo
18630941METHODS OF IDENTIFYING MULTIPLE EPITOPES IN CELLSApril 2024August 2024Allow400YesNo
18594336METHODS FOR MONITORING RESIDUAL DISEASEMarch 2024July 2024Allow410NoNo
18317177OLIGONUCLEOTIDE AND USE THEREOF AGAINST HEPATITIS B VIRUS AND HEPATITIS D VIRUSMarch 2024December 2024Abandon2010NoNo
18588765METHODS OF AMPLIFYING CIRCULAR POLYNUCLEOTIDES IN SITUFebruary 2024August 2024Allow620NoNo
18582279COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDFebruary 2024February 2025Allow1220NoNo
18436821METHODS FOR EARLY DETECTION OF CANCERFebruary 2024August 2024Allow610NoNo
18427866SIGNAL BOOST CASCADE ASSAYJanuary 2024July 2024Allow530NoNo
18425327MULTIPLE LAMP PRIMER SET, DETECTION METHOD, AND KIT FOR SIMULTANEOUS DETECTION OF MULTIPLE PATHOGENSJanuary 2024August 2024Allow620NoNo
18574729MUTATION SITE OF IDEAL BRITTLE CULM MUTANT ibc IN RICE, CONTROLLING GENE IBC, AND USE THEREOFDecember 2023July 2024Allow600NoNo
18538986METHODS AND SYSTEMS FOR DETECTING GENETIC VARIANTSDecember 2023August 2024Allow810NoNo
18535485METHODS AND SYSTEMS FOR DETECTING GENETIC VARIANTSDecember 2023April 2024Allow410NoNo
18535812SYSTEMS AND METHODS TO DETECT RARE MUTATIONS AND COPY NUMBER VARIATIONDecember 2023August 2024Allow910NoNo
18532300MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOFDecember 2023April 2025Allow1621YesNo
18524856COMPOSITIONS AND METHODS FOR INCREASED PROTEIN PRODUCTION IN BACILLUS LICHENIFORMISNovember 2023June 2025Allow1910YesNo
18523746Compounds and Methods for Reducing LRRK2 ExpressionNovember 2023August 2024Allow900NoNo
18523743DIAGNOSTIC KIT FOR METASTASIS AND INVASION OF BREAST CANCER AND USE OF shRNA MOLECULE FOR SILENCING EXPRESSION OF HUMAN LINC01614November 2023March 2025Allow1520NoNo
18520939DNA Methylation Analysis to Identify Cell TypeNovember 2023June 2024Allow610NoNo
18519727SAFE SEQUENCING SYSTEMNovember 2023April 2024Allow511NoNo
18514645DIGITAL ANALYTE ANALYSISNovember 2023April 2024Allow511NoNo
18507175METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDERNovember 2023May 2025Abandon1801NoNo
18504952SINGLE-VECTOR TYPE I VECTORSNovember 2023May 2025Allow1810YesNo
18387017cGMP EXOSOME LOADED THERAPEUTICS FOR TREATING SICKLE CELL DISEASENovember 2023January 2025Allow1520YesNo
18498577ADENO-ASSOCIATED VIRUS (AAV) PRODUCER CELL LINESOctober 2023May 2025Allow1821YesNo
18491071METHODS AND SYSTEMS FOR DETECTING GENETIC VARIANTSOctober 2023April 2024Allow610NoNo
16500637METHOD FOR QUANTITATIVELY CONTROLLING PLASMID COPY NUMBER IN ANTIBIOTIC-FREE PLASMID MAINTENANCE SYSTEMOctober 2023January 2025Allow6011YesNo
18487610SYSTEMS, METHODS, AND COMPOSITIONS FOR SITE-SPECIFIC GENETIC ENGINEERING USING PROGRAMMABLE ADDITION VIA SITE-SPECIFIC TARGETING ELEMENTS (PASTE)October 2023August 2024Allow1010NoNo
18485615Methods of Detecting Bladder CancerOctober 2023May 2025Allow1920YesNo
18379589METHOD FOR LABELING LIGATION PRODUCTS WITH CELL-SPECIFIC BARCODES IIOctober 2023February 2024Allow400YesNo
18379586METHOD FOR LABELING LIGATION PRODUCTS WITH CELL-SPECIFIC BARCODES IOctober 2023January 2024Allow300NoNo
18484291PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOFOctober 2023May 2025Abandon2001NoNo
18371373METHODS FOR NON-INVASIVE PRENATAL PLOIDY CALLINGSeptember 2023June 2024Abandon901NoNo
18283172SPATIAL MAPPING BY SERIAL PRIMER EXTENSIONSeptember 2023August 2024Allow1110NoNo
18470619MOLECULAR DETECTION UNIT, CHIP AND PREPARATION METHODSeptember 2023February 2024Allow510NoNo
18467224COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNASSeptember 2023November 2024Allow1431YesNo
18467190COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTSSeptember 2023April 2024Allow710NoNo
18463589TARGETED NON-VIRAL DNA INSERTIONSSeptember 2023October 2024Allow1310YesNo
18242277SYSTEM AND METHOD FOR COLD ATMOSPHERIC PLASMA BASED T CELL THERAPYSeptember 2023January 2025Abandon1610NoNo
18240904SYSTEM AND SELF-METERING CARTRIDGES FOR POINT OF CARE BIOASSAYSAugust 2023August 2024Abandon1220NoNo
18236540PROBE-BASED ANALYSIS OF NUCLEIC ACIDS AND PROTEINSAugust 2023January 2024Allow510NoNo
18452514COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSIONAugust 2023November 2024Allow1520YesNo
18234402SIGNAL BOOST CASCADE ASSAYAugust 2023January 2024Allow511NoNo
18450212AP50 POLYMERASES AND USES THEREOFAugust 2023May 2024Allow1000NoNo
18449601CLEAVABLE DISULFIDE LINKERS AND USES THEREOFAugust 2023December 2023Allow400NoNo
18448618METHODS FOR IDENTIFYING A LOCATION OF AN RNA IN A BIOLOGICAL SAMPLEAugust 2023February 2024Allow620NoNo
18233214Barcoded Beads and Method for Making the Same by Split-Pool SynthesisAugust 2023October 2023Allow300YesNo
18233221Kit for Split-Pool Barcoding Target Molecules That Are In or On Cells or Cell OrganellesAugust 2023November 2023Allow300YesNo
18365129DETERMINATION OF PROTEIN INFORMATION BY RECODING AMINO ACID POLYMERS INTO DNA POLYMERSAugust 2023May 2024Allow1020YesNo
18364429METHODS AND SYSTEMS FOR SAMPLE ANALYSISAugust 2023March 2024Allow711NoNo
18361363Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses ThereofJuly 2023May 2024Allow911NoNo
18226933METHODS, COMPOSITIONS, AND KITS FOR BLOCKING A CAPTURE PROBE ON A SPATIAL ARRAYJuly 2023October 2023Allow310NoNo
18356724SPATIAL SEQUENCINGJuly 2023March 2024Allow820NoNo
18356770OLIGONUCLEOTIDES FOR MODULATING TAU EXPRESSIONJuly 2023December 2024Abandon1701NoNo
18352347CONSTRUCTS FOR CONTINUOUS MONITORING OF LIVE CELLSJuly 2023October 2024Allow1510YesNo
18260789USE OF GANODERMA FUNGAL RNA MOLECULES, DRUG, DRUG COMPOSITION AND DELIVERY CARRIERJuly 2023May 2025Allow2220NoNo
18219545METHODS FOR ANALYZING BIOLOGICAL SAMPLES IN A FLUIDIC DEVICE COMPRISING GENERATING A POLYMER MATRIX FROM PRECURSORS AT DISCRETE AREASJuly 2023January 2024Allow710YesNo
18219104OIL AND GAS EXPLORATION METHOD BASED ON MICROBIAL GENEJuly 2023March 2024Allow811YesNo
18346686NUCLEIC ACIDS ENCODING CRISPR-ASSOCIATED PROTEINS AND USES THEREOFJuly 2023March 2025Allow2001NoNo
18345407THERAPEUTIC OLIGONUCLEOTIDESJune 2023April 2025Allow2111NoNo
18334632MODULATORS OF HSD17B13 EXPRESSIONJune 2023September 2023Allow310NoNo
18333436SYSTEMS AND METHODS TO DETECT RARE MUTATIONS AND COPY NUMBER VARIATIONJune 2023September 2023Allow310NoNo
18333007Selective Antisense Compounds and Uses ThereofJune 2023March 2025Abandon2101NoNo
18330935OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAMEJune 2023August 2024Abandon1510NoNo
18330356ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSIONJune 2023January 2025Allow2020NoNo
18327434RECONFIGURABLE DNA NANO-TWEEZERJune 2023March 2025Allow2210NoNo
18326300UNIVERSAL PROBE, PRIMER-PROBE SET AND KITMay 2023March 2024Allow1011NoNo
18326588METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCESMay 2023November 2024Allow1720YesNo
18319889NUCLEIC ACID LIBRARY METHODSMay 2023October 2023Allow510NoNo
18317550METHODS AND SYSTEMS FOR DETECTING GENETIC VARIANTSMay 2023August 2024Allow1510NoNo
18316870METHODS AND SYSTEMS FOR DETECTING GENETIC VARIANTSMay 2023May 2024Allow1210YesNo
18316864METHODS AND SYSTEMS FOR DETECTING GENETIC VARIANTSMay 2023August 2023Allow410NoNo
18314258RNA-Editing Oligonucleotides and Uses ThereofMay 2023August 2024Allow1521NoNo
18314411HUMAN INNATE LYMPHOID CELL PRECURSORS: IDENTIFICATION, CHARACTERIZATION, APPLICATIONSMay 2023May 2025Abandon2520NoNo
18313227SHORT PENDANT ARM LINKERS FOR NUCLEOTIDES IN SEQUENCING APPLICATIONSMay 2023April 2024Allow1110NoNo
18312328ENGINEERED MEGANUCLEASES SPECIFIC FOR RECOGNITION SEQUENCES IN THE PCSK9 GENEMay 2023December 2024Abandon1910NoNo
18312334ENGINEERED MEGANUCLEASES SPECIFIC FOR RECOGNITION SEQUENCES IN THE PCSK9 GENEMay 2023January 2025Abandon2010NoNo
18307666FETAL SEX DETERMINATION USING CAPILLARY BLOOD FROM UPPER ARMApril 2023January 2024Allow920NoNo
18306023GENETIC SEX-DETERMINATION METHODApril 2023March 2024Allow1130YesNo
18136632SAMPLE EXTRACTION DEVICE AND METHODS OF USING THE SAMEApril 2023August 2024Abandon1601NoNo
18135073TEMPERATURE CONTROLLED VALVES FOR PAPER-BASED MICROFLUIDIC SYSTEMSApril 2023August 2024Allow1620NoNo
18134003METHODS OF IDENTIFYING MULTIPLE EPITOPES IN CELLSApril 2023August 2023Allow400NoNo
18295770NUCLEOTIDE ANALOGUESApril 2023November 2023Allow710NoNo
18130278METHODS AND COMPOSITIONS FOR TREATING A PREMATURE STOP CODON-MEDIATED DISORDERApril 2023December 2024Abandon2110NoNo
18192191INDUCIBLE CRISPR SYSTEM EXPRESSION AND APPLICATIONS THEREOFMarch 2023December 2024Allow2030YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1637.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
187
Examiner Affirmed
131
(70.1%)
Examiner Reversed
56
(29.9%)
Reversal Percentile
37.8%
Lower than average

What This Means

With a 29.9% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
1195
Allowed After Appeal Filing
233
(19.5%)
Not Allowed After Appeal Filing
962
(80.5%)
Filing Benefit Percentile
5.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 19.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1637 - Prosecution Statistics Summary

Executive Summary

Art Unit 1637 is part of Group 1630 in Technology Center 1600. This art unit has examined 14,297 patent applications in our dataset, with an overall allowance rate of 57.2%. Applications typically reach final disposition in approximately 34 months.

Comparative Analysis

Art Unit 1637's allowance rate of 57.2% places it in the 12% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1637 receive an average of 2.05 office actions before reaching final disposition (in the 70% percentile). The median prosecution time is 34 months (in the 23% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.